BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 15488390)

  • 1. The LCR of EBV makes Burkitt's lymphoma endemic.
    Niller HH; Salamon D; Banati F; Schwarzmann F; Wolf H; Minarovits J
    Trends Microbiol; 2004 Nov; 12(11):495-9. PubMed ID: 15488390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EBV-associated neoplasms: alternative pathogenetic pathways.
    Niller HH; Salamon D; Ilg K; Koroknai A; Banati F; Schwarzmann F; Wolf H; Minarovits J
    Med Hypotheses; 2004; 62(3):387-91. PubMed ID: 14975509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
    Niller HH; Salamon D; Ilg K; Koroknai A; Banati F; Bauml G; Rucker O; Schwarzmann F; Wolf H; Minarovits J
    Med Sci Monit; 2003 Jan; 9(1):HY1-9. PubMed ID: 12552250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.
    Kelly G; Bell A; Rickinson A
    Nat Med; 2002 Oct; 8(10):1098-104. PubMed ID: 12219084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines.
    Pokrovskaja K; Ehlin-Henriksson B; Bartkova J; Bartek J; Scuderi R; Szekely L; Wiman KG; Klein G
    Cell Growth Differ; 1996 Dec; 7(12):1723-32. PubMed ID: 8959341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines.
    Perez-Chacon G; de Los Rios C; Zapata JM
    Pharmacol Res; 2014 Nov; 89():46-56. PubMed ID: 25180456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
    Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
    J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Epstein-Barr virus latent gene expression on the apoptosis-inducing effects of cortisone and 2-chlorodeoxyadenosine (2-CDA) in B-cell lines.
    Röth A; Pfaff P; Lange W; Finke J
    Cytokines Mol Ther; 1996 Mar; 2(1):21-8. PubMed ID: 9384686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus and oncogenesis: from latent genes to tumours.
    Young LS; Murray PG
    Oncogene; 2003 Aug; 22(33):5108-21. PubMed ID: 12910248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
    De Leo A; Arena G; Stecca C; Raciti M; Mattia E
    Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EBV-B cell interactions: immortalization, rescue from apoptosis, tumorigenicity (a short review).
    Klein G
    Acta Microbiol Immunol Hung; 1996; 43(2-3):97-105. PubMed ID: 8876725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell phenotype-dependent splicing reflecting differential promoter usage for EBNA transcripts in EBV-carrying cells.
    Hu LF; Chen F; Altiok E; Winberg G; Klein G; Ernberg I
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():248-60. PubMed ID: 10895161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
    Staege MS; Lee SP; Frisan T; Mautner J; Scholz S; Pajic A; Rickinson AB; Masucci MG; Polack A; Bornkamm GW
    Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4550-5. PubMed ID: 11917131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Burkitt lymphoma--a stalking horse for cancer research?
    Klein G
    Semin Cancer Biol; 2009 Dec; 19(6):347-50. PubMed ID: 19607918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated expression of c-myc in lymphoblastoid cells does not support an Epstein-Barr virus latency III-to-I switch.
    Pajic A; Polack A; Staege MS; Spitkovsky D; Baier B; Bornkamm GW; Laux G
    J Gen Virol; 2001 Dec; 82(Pt 12):3051-3055. PubMed ID: 11714983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus: 40 years on.
    Young LS; Rickinson AB
    Nat Rev Cancer; 2004 Oct; 4(10):757-68. PubMed ID: 15510157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas.
    Kennedy G; Komano J; Sugden B
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14269-74. PubMed ID: 14603034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus encoded BALF1 gene is transcribed in Burkitt's lymphoma cell lines and in nasopharyngeal carcinoma's biopsies.
    Cabras G; Decaussin G; Zeng Y; Djennaoui D; Melouli H; Broully P; Bouguermouh AM; Ooka T
    J Clin Virol; 2005 Sep; 34(1):26-34. PubMed ID: 16087121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etiology of endemic Burkitt's lymphoma.
    Olweny CL
    IARC Sci Publ; 1984; (63):647-53. PubMed ID: 6100285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epstein-Barr virus and Burkitt's lymphoma].
    Joab I
    Med Trop (Mars); 1999; 59(4 Pt 2):499-502. PubMed ID: 10901854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.